Compound Reduces Damage From TBI

Researchers Report Thymosin Beta 4 Significantly Reduces Damage From Traumatic Brain Injury And Improves Brain Function In Experimental Animals 05/26/2010.  RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) announced today that in a preclinical research paper published in the May 2010 issue of the Journal of Neurosurgery, (online ahead of publication), scientists found that the systemic administration of thymosin beta 4, or Tβ4, significantly reduced brain tissue damage and improved brain function in rats with traumatic brain injury, or TBI. RegeneRx Biopharmaceuticals, Inc. via Medical News Today